Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran.
Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Int J Biol Macromol. 2022 Nov 30;221:604-612. doi: 10.1016/j.ijbiomac.2022.09.020. Epub 2022 Sep 7.
Triple-negative breast cancer (TNBC) has the worst prognosis among all breast cancer subtypes. The lack of proper treatments prompted scientists to find a practical targeted therapy to treat this type of tumor. Based on previous studies, tyrosine kinase-like orphan receptor (ROR1) is overexpressed in TNBC cells. Here, we designed a system consisting of superparamagnetic iron oxide nanoparticles (SPIONs) decorated with silk sericin (SS NPs) for the targeted delivery of ROR1 siRNA, a gene silencer to knockdown the expression of human ROR1 gene. NPs exhibited spherical shape of about 193 nm with acceptable properties both in vitro and in vivo. The apoptosis study showed significant death of MDA-MB-231 cells after 24 h treatment with the prepared NPs. The real-time PCR study also demonstrated an almost complete shutdown of ROR1 expression. Guided by magnetic field, enhanced accumulation of NPs was observed in breast tumors induced by 4T1 cells in BALB/c mice. Histological evaluation of the tumor exhibited necrosis 14 days post-treatment with the siRNA-loaded NPs; whereas, the untreated tumor was proliferating. Also, the tumor growth rate was significantly decreased after treatment with siRNA-loaded NPs in vivo. In conclusion, the prepared delivery system could be considered as a potential therapeutic strategy for treating TNBC.
三阴性乳腺癌(TNBC)是所有乳腺癌亚型中预后最差的。由于缺乏适当的治疗方法,科学家们正在寻找一种实用的靶向治疗方法来治疗这种肿瘤。基于之前的研究,酪氨酸激酶样孤儿受体(ROR1)在 TNBC 细胞中过表达。在这里,我们设计了一个由超顺磁性氧化铁纳米粒子(SPIONs)修饰丝胶(SS NPs)组成的系统,用于靶向递送 ROR1 siRNA,这是一种基因沉默物,可降低人 ROR1 基因的表达。NPs 呈球形,约 193nm,具有可接受的体外和体内性能。凋亡研究表明,用制备的 NPs 处理 MDA-MB-231 细胞 24 小时后,细胞死亡显著。实时 PCR 研究还表明 ROR1 表达几乎完全关闭。在 BALB/c 小鼠中,由 4T1 细胞诱导的乳腺癌中,磁场引导下观察到 NPs 的增强积累。治疗 14 天后,用负载 siRNA 的 NPs 处理的肿瘤表现出坏死;而未经处理的肿瘤则在增殖。此外,体内用负载 siRNA 的 NPs 治疗后,肿瘤生长速度显著降低。总之,所制备的递药系统可被视为治疗 TNBC 的一种潜在治疗策略。
Breast Cancer Res. 2022-6-3
J Immunother Cancer. 2020-4
Virchows Arch. 2016-5
Front Pharmacol. 2025-2-12
Biomed Microdevices. 2024-2-7
Cancers (Basel). 2023-4-12
Chonnam Med J. 2023-1